Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

Market Cap	5.50B
Revenue (ttm)	1.39B
Net Income (ttm)	73.99M
Shares Out	219.83M
EPS (ttm)	0.34
PE Ratio	73.86
Forward PE	36.00
Dividend	0.05 (0.19%)
Ex-Dividend Date	Jun 25, 2025

Volume	47,810,528
Average Volume	31,817,744
Open	23.90
Previous Close	23.70
Day's Range	23.90 - 26.07
52-Week Range	9.99 - 28.00
Beta	0.50
RSI	47.74
Earnings Date	Aug 27, 2025

About SHA:603538

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. Ningbo Menovo Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Ningbo, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 2,472
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603538

Financial Performance

In 2024, SHA:603538's revenue was 1.37 billion, an increase of 12.85% compared to the previous year's 1.22 billion. Earnings were 66.81 million, an increase of 476.64%.